Document is current
Any future updates will be listed below
-
Authors
Wegmann, Rebekka https://orcid.org/0000-0001-9616-3303
Bankel, Lorenz https://orcid.org/0000-0002-4650-7830
Festl, Yasmin
Lau, Kate
Lee, Sohyon
Arnold, Fabian
Cappelletti, Valentina
Fehr, Aaron https://orcid.org/0009-0006-7818-5297
Picotti, Paola
Dedes, Konstantin J.
Franzen, Daniel
Lenggenhager, Daniela https://orcid.org/0000-0002-5382-9854
Bode, Peter K.
Zoche, Martin https://orcid.org/0000-0002-0421-7229
Moch, Holger https://orcid.org/0000-0002-7986-2839
Britschgi, Christian
Snijder, Berend https://orcid.org/0000-0003-3386-6583
- License Information
-
More Information
Article History
Received: 14 June 2024
Accepted: 12 September 2024
First Online: 2 October 2024
Competing interests
: B.S. was a scientific co-founder of Allcyte, which has been acquired by Exscientia. B.S. is a shareholder of Exscientia and a co-inventor on US patent application 15/514,045 relevant to the study. C.B. reports consulting or advisory role for AstraZeneca, Pfizer, Roche, Takeda, Janssen-Cilag, Boehringer-Ingelheim, Merck KGaA, Sanofi; research funding from Bayer; and travel, accommodation, and expenses from AstraZeneca, Takeda, Amgen. All of those are outside the presented work. H.M. is on advisory boards for Astra Zeneca, Stemline Therapeutics, Bayer, Amgen, Astella, MSD, Roche, and Merck. M.Z. receives research funds from Roche. P.P. is a scientific advisor for the company Biognosys AG (Zurich, Switzerland). All other authors declare no competing interests.
